SOURCE: TapImmune Inc.

January 16, 2008 08:30 ET

TapImmune Retains ROI Group as Investor Relations Counsel

VANCOUVER, BC--(Marketwire - January 16, 2008) - TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced it has retained ROI Group LLC as investor relations counsel.

"TapImmune is rapidly moving forward on management's strategies to take our therapeutic TAP vaccine into clinical trials as soon as possible. We anticipate commencing viral constructs and production very shortly. This will be followed by final toxicology studies on AdhTAP, the preparation of the protocol for clinical trials and a filing for an Investigational New Drug (IND) by the end of 2008," TapImmune CEO Denis Corin said.

"Developing and marketing our adjuvant to potential partners over the course of the year, initiating clinical trials and expanding our solid and broad intellectual property portfolio, will, I believe, create increased value for our shareholders. TapImmune represents a compelling investment story, and now is the time to expand our efforts in sharing our story with potential investors throughout the financial community," added Mr. Corin.

"TapImmune's patented technologies target two substantial areas within the vaccine market that have not been adequately served. We believe TapImmune represents an exceptional growth opportunity as the potential markets it addresses are billions of dollars in size. Our efforts will be focused on broadening the understanding of TapImmune's exciting investment potential amongst various members of the financial community," stated Mr. Michael Dodge, Senior Account Manager, ROI Group.

About TapImmune Inc.

TapImmune Inc. is a biotechnology Company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidate, in preclinical tests has been shown to restore and augment antigen presentation and subsequent recognition and elimination of cancer cells by the immune system.

TapImmune is preparing GLP manufactured materials for the commencement of toxicology studies on the AdhTAP vaccine, leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells.

Additional information on the Company can be found on its web site

Safe Harbor Statement

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

Contact Information